Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BRAIN Biotech AG's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.10.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.40.
During the past 3 years, the average EBIT per Share Growth Rate was -3.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 2.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 5.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for BRAIN Biotech AG's EBIT per Share or its related term are showing as below:
HAM:BNN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -11.7 Med: 4.45 Max: 30.8
Current: -3.5
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of BRAIN Biotech AG was 30.80% per year. The lowest was -11.70% per year. And the median was 4.45% per year.
HAM:BNN's 3-Year EBIT Growth Rate is ranked worse than 52.54% of 1338
companies
in the Chemicals industry
Industry Median: -1.2
vs HAM:BNN: -3.50
BRAIN Biotech AG (HAM:BNN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
BRAIN Biotech AG EBIT per Share Related Terms
BRAIN Biotech AG EBIT per Share Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG (HAM:BNN) has a EBIT per Share of €-0.40 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BRAIN Biotech AG and its competitors. According to the industry distribution chart, BRAIN Biotech AG ranks #703 out of 1338 companies in the Chemicals industry, placing it in the top 52.5%.
Is BRAIN Biotech AG's EBIT per Share too high?
BRAIN Biotech AG's current EBIT per Share is €-0.40. Based on the distribution chart, BRAIN Biotech AG ranks #703 out of 1338 companies in the Chemicals industry, which is below the industry midpoint. Overall, BRAIN Biotech AG has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's EBIT per Share compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #703 out of 1338 companies for EBIT per Share. This places BRAIN Biotech AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Chemicals company?
A good EBIT per Share depends on the Chemicals industry context. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current EBIT per Share is €-0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.49, compared to a current price of €2.80 — trading 12.4% above its estimated fair value. The current EBIT per Share is €-0.40. BRAIN Biotech AG's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current EBIT per Share is €-0.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.80 is trading 12.4% above its estimated GF Value™ of €2.49.
GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.
Key valuation signals for HAM:BNN:
EBIT per Share: €-0.40
GF Value™: €2.49 vs. price of €2.80 (12.4% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
68GF Score
Get the complete analysis for HAM:BNN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
